SCHEMBL860115

SCHEMBL860115

CN1C(=O)NC(=O)C1=Cc1cnn2ccc(Nc3cccc(Cl)c3)nc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 7/20 0.37
CSNK2B P67870 5/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
CYP1A2 P05177 1/20 0.36
POLB P06746 1/20 0.36
HSP90AA1 P07900 1/20 0.36
CYP3A4 P08684 1/20 0.36
MAPT P10636 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.36
CYP2C19 P33261 1/20 0.36
KMT2A Q03164 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PRKDC P78527 1/20 0.36
PIM2 Q9P1W9 5/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12978888 1.00 PIM1 (0.37) PIM1CSNK2BKDM4EMEN1CYP1A2
SCHEMBL860114 1.00 PIM1 (0.37) PIM1CSNK2BKDM4EMEN1CYP1A2
SCHEMBL861026 0.83 CSNK2B (0.46) PIM1CSNK2BKDM4EHPGDMAPK1
SCHEMBL12978737 0.83 CSNK2B (0.46) PIM1CSNK2BKDM4EHPGDMAPK1
SCHEMBL861027 0.83 CSNK2B (0.46) PIM1CSNK2BKDM4EHPGDMAPK1
SCHEMBL861502 0.81 PIM1 (0.49) PIM1MEN1MAPTKMT2APIM2
SCHEMBL861503 0.81 PIM1 (0.49) PIM1MEN1MAPTKMT2APIM2
SCHEMBL12978877 0.81 PIM1 (0.49) PIM1MEN1MAPTKMT2APIM2
SCHEMBL1487786 0.81 SMN1; SMN2 (0.38) PIM1CSNK2BMEN1MAPTKMT2A
SCHEMBL1487822 0.81 CSNK2B (0.44) PIM1CSNK2BPIM2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367681-B2 Pyrazolopyrimidines and related heterocycles as kinase inhibitors CYLENE PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
EP-2432473-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS Cylene Pharmaceuticals, Inc. (US) 2012-03-28 EP disclosed
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
WO-2010135581-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS PIM1, PIM2, PIM3 PIM1 1/4885CSNK2B 71/4885KDM4E 1856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.